Morgan Lewis Advised Cyclerion Therapeutics in Exclusive Agreement with Akebia

BOSTON, June 7, 2021: Morgan Lewis represented Cyclerion Therapeutics Inc. in a licensing agreement with Akebia Therapeutics Inc. for the development and commercialization of praliciguat, an oral soluble guanylate cyclase (sGC) stimulator.

Cyclerion is a clinical-stage biopharmaceutical company on a mission to develop treatments that restore cognitive function. Akebia is a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

Morgan Lewis life sciences transactions associate Andrew Haupt represented Cyclerion.

For more, read Cyclerion’s announcement.